<DOC>
	<DOCNO>NCT01075191</DOCNO>
	<brief_summary>Therapy lopinavir/ritonavir ( Kaletra ) one protease inhibitor Human Immunodeficiency Virus participant</brief_summary>
	<brief_title>Kaletra : Therapy With Double Protease Inhibitors</brief_title>
	<detailed_description>This study intend observe collect data usage , dose , tolerability , effectiveness lopinavir/ritonavir ( Kaletra ) use part Nucleoside Reverse Transcriptase Inhibitors-free double protease regimen . Enrollment study independent decision prescribe Kaletra .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Participants Human Immunodeficiency Virus infection Participants lopinavir/ritonavir ( Kaletra ) one protease inhibitor Hypersensitivity lopinavir , ritonavir ingredient Severe liver insufficiency No concomitant astemizole , terfenadine , oral midazolam , triazolam , cisapride , pimozide , amiodarone , ergotamine , dihydroergotamine , ergometrine , methylergometrine , vardenafil St. John 's wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Viral load</keyword>
	<keyword>Resistance</keyword>
	<keyword>Double protease inhibitor</keyword>
	<keyword>Mutations</keyword>
	<keyword>Immune system</keyword>
	<keyword>Infection</keyword>
	<keyword>Nucleoside Reverse Transcriptase Inhibitors-free</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>